ATAI Life Sciences NV (FRA:9VC) ROCE % : -37.97% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is ATAI Life Sciences NV ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ATAI Life Sciences NV's annualized ROCE % for the quarter that ended in Mar. 2024 was -37.97%.

ATAI Life Sciences NV ROCE % Historical Data

The historical data trend for ATAI Life Sciences NV's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ATAI Life Sciences NV ROCE % Chart

ATAI Life Sciences NV Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-13.51

-111.35

-49.58

-41.05

-12.91

ATAI Life Sciences NV Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial													-47.38	-49.65	68.42	-24.82	-37.97

ATAI Life Sciences NV ROCE % Calculation

ATAI Life Sciences NV's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-33.59	/	( ( (288.336 - 18.783)	+	(269.119 - 18.45) )	/ 2 )
	=	-33.59	/	( (269.553	+	250.669)	/ 2 )
	=	-33.59	/	260.111
	=	-12.91 %

ATAI Life Sciences NV's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-91.976	/	( ( (269.119 - 18.45)	+	(247.591 - 13.812) )	/ 2 )
	=	-91.976	/	( ( 250.669	+	233.779 )	/ 2 )
	=	-91.976	/	242.224
	=	-37.97 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

ATAI Life Sciences NV (FRA:9VC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ATAI Life Sciences NV ROCE % Related Terms

Thank you for viewing the detailed overview of ATAI Life Sciences NV's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

ATAI Life Sciences NV (FRA:9VC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ATAI Life Sciences NV (FRA:9VC) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ATAI:USA ATAI:Mexico

Address

Wallstraße 16, Berlin, BB, DEU, 10179

Website

https://www.atai.life

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.

ATAI Life Sciences NV (FRA:9VC) Headlines

No Headlines